For the role of CD8+ T-cells in disease regression, a comparison of CD8+ T-cell responses to E6 and E7 using enzyme-linked immunospot assays in individuals with incident or prevalent HPV 16 or 18 infections did not show any significant difference in the frequency of positivity between these two patient groups (33 vs. 40%) (75). The gene discussed is CD8A; the disease is infection.